Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Grant to enable nonprofit organizations in the Food Is Medicine Coalition to expand services for medically-tailored meals for individuals with chronic medical conditions. DENVER , Oct. 10, 2022 /PRNewswire/ -- The DaVita Giving Foundation, a private charitable organization created by DaVita Inc., today announced a $1.4 million grant to the Food Is Medicine Coalition (FIMC), a national association of 25 nonprofit organizations across the country focused on addressing the dual crises of illness and hunger.

The DaVita Giving Foundation Provides $1.4 Million Grant Toward Addressing Food Insecurity

The Health Care sector has been a source of relative safety during this tumultuous September. While some large-caps in the space are catching bids, one smaller health care services and facilities company is sharply lower in 2022.

DaVita: Solid Valuation And Cash Flow, Price Recovering After SCOTUS Ruling

Boyd Gaming

Coca-Cola Bottling

Graham Holdings

Nexstar Media Group

Prestige Brands Holdings

Sprouts Farmers Markets

It's up for debate whether the stock market downturn has reached or is close to reaching the “bottoming out” stage, but there are many opportunities out there. While most of the best opportunities are among stocks of the small-cap/”unknown” variety, there are also plenty of undervalued mid-cap stocks to buy now trading at low valuations.

The 7 Most Undervalued Mid-Cap Stocks to Buy Now

DENVER , Sept. 13, 2022 /PRNewswire/ -- DaVita Inc. announced today that its Board of Directors appointed a new independent director, Adam H.

DaVita Announces Adam H. Schechter to Join its Board of Directors

OKLAHOMA CITY--(BUSINESS WIRE)-- #DVA--Federman & Sherwood Investigates DaVita, Inc. for Data Breach

Federman & Sherwood Investigates DaVita, Inc. for Data Breach

Ally Financial

Bank of America

Citigroup

Celanese

Chevron

General Motors

Occidental Petroleum

U.S. Bancorp

These Berkshire Hathaway holdings sport forward-year price-to-earnings (P/E) ratios of 4.8 to 9.2.

The 10 Cheapest Warren Buffett Stocks

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?

DaVita HealthCare (DVA) Up 0.7% Since Last Earnings Report: Can It Continue?

Builders FirstSource

Chegg

Charter Communications

Freeport-McMoRan

Macy's

StoneCo

Undervalued stocks are  businesses that trade below their intrinsic value.  Thomas Chua is the author of the 3-Bullet Sunday investment newsletter.

7 Undervalued Stocks That Everyone Is Missing Out On

Warren Buffett loves to own cash-generating "toll bridge" companies. DaVita qualifies on both counts.

Down 26%, Is This Buffett Stock a Buy?

DaVita (DVA) records an overall solid Q2 performance owing to strength in its Other segment's revenues and uptick in total U.S. dialysis treatments.

DaVita (DVA) Beats on Q2 Earnings, Reiterates FY22 EPS View

DaVita Inc. (NYSE:DVA ) Q2 2022 Earnings Conference Call August 1, 2022 5:00 PM ET Corporate Participants Joel Ackerman - Chief Financial Officer and Treasurer Javier Rodriguez - Chief Executive Officer Conference Call Participants Kevin Fischbeck - Bank of America Justin Lake - Wolfe Research Pito Chickering - Deutsche Bank Sarah James - Barclays Gary Taylor - Cowen Operator Good evening. My name is Michelle, and I'll be your conference facilitator today.

DaVita Inc. (DVA) CEO Javier Rodriguez on Q2 2022 Results - Earnings Call Transcript

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 9% and 0.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

DaVita HealthCare (DVA) Tops Q2 Earnings Estimates

DENVER , Aug. 1, 2022 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2022. "We are living in a dynamic time with a sustained global pandemic, labor shortage, supply chain disruption, and more.

DaVita Inc. 2nd Quarter 2022 Results

Johnson & Johnson

McKesson

These unstoppable companies can succeed in pretty much any economic condition.

3 No-Brainer Warren Buffett Stocks That Will Undeniably Profit from the Bear Market

American Diabetes Association and DaVita launch a digital experience with resources for preventing and managing diabetes-related kidney complications ARLINGTON, Va. and DENVER , July 25, 2022 /PRNewswire/ -- The American Diabetes Association® (ADA), along with DaVita, are excited to announce the launch of an interactive digital experience aimed at helping those living with diabetes prevent and manage kidney disease.

American Diabetes Association Focuses on Prevention of Kidney Disease through Collaboration with DaVita

American Express

Bank of New York Mellon

Globe Life Inc

Coca-Cola

Mastercard

Moody's

Mondelez

Procter & Gamble

Visa

Patience plays a big role in the Oracle of Omaha's investing philosophy.

15 Stocks Warren Buffett Has Held for at Least 10 Years

DENVER , July 18, 2022 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Monday, August 1, 2022, at 5:00 p.m. Eastern Time.

DaVita Inc. Schedules 2nd Quarter 2022 Investor Conference Call

DaVita's recent performance highlights its exposure to regulatory risk and its limitations as a business to proactively generate growth. We expect to see a recovery YoY into FY12/2023 driven primarily by normalizing conditions.

DaVita: Valuation Turning Attractive

AMN Healthcare Services

Elevance Health Inc

HCA Healthcare

UnitedHealth Group

U.S. market indexes kicked off the week lower as investors prepare for the start of second-quarter earnings season.

5 Undervalued Predictable Health Care Stocks

Something I have been thinking about recently is the possibility of Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) and Warren Buffett (Trades, Portfolio) making an offer for a company that has seen its share price decline significantly over the past couple of months.

2 Potential Berkshire Acquisitions

Kraft Heinz

Liberty Media Corp-Liberty SiriusXM

Based on how big a slice of the pie is owned, these could be viewed as Warren Buffett's favorite stocks.

3 Stocks Warren Buffett Owns the Biggest Percentage Stakes In (Hint: Apple Isn't 1 of Them)

Chesapeake Energy

Kyndryl Holdings

Plains All American Pipeline

Rocket Companies, Inc.

These are 6 stocks insiders are buying now. Execs buying shares now want to get in before Q2 earnings come out - a good sign for investors.

6 Stocks Insiders Are Buying Now

DaVita HealthCare (DVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

DaVita HealthCare (DVA) Surges 6%: Is This an Indication of Further Gains?

Rockwell Medical

- Closes $7.5 Million Second Tranche Investment from DaVita -  $30 Million in Total Capital Raised This Quarter - Receives Additional Feedback from FDA on its IND Application WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients, today provided an update on its recent capital raise and a clinical update on safety enhancements to its planned Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC) in home infusion patients.

Rockwell Medical Provides Corporate and Clinical Update

DENVER , June 22, 2022 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today it will hold a special conference call with investors on Thursday, June 23, 2022, at 8:45 a.m. Eastern Time.

News for DaVita Stock (DVA)